p-AKT Expression on Clinical Outcomes in Malignant Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

262 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

NCT01761682

Leukemia, Acute Lymphoblastic Precursor B-Cell Lymphoblastic Leukemia Leukemia, Biphenotypic, Acute +2 more

TERMINATED

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

NCT05867030

Follicular Lymphoma

WITHDRAWN PHASE1

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

NCT01307267

Lymphoma, Non-Hodgkin Lymphoma, Follicular Lymphoma, Large B-Cell, Diffuse +4 more

COMPLETED PHASE1

PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

NCT07207785

Mantle Cell Lymphoma

NOT_YET_RECRUITING PHASE2

Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults

NCT01809600

Burkitt's Lymphoma High-grade B-cell Lymphoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B \[PKB\]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers.

However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Lymphoma P13K-AKT Pathway Deregulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

p-AKT

p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)

p-AKT immunohistochemical staining

Intervention Type OTHER

p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

p-AKT immunohistochemical staining

p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification;
2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.